Numbers can certainly be consolidated through this SAS for RRV.
If you were one of the 95% of between 4,000 and 5,000 people a year in Aus. that contract it, then I can't see why you wouldn't try the novel treatment for a disease that obviously sucks to have.
I think this news is much bigger than the market even realises. When added to the OA SAS which is coming as well, it will show whether this product is the real deal or not (I am betting on the former).
The money for my shots (a few $K I figure) is just sitting there waiting in the drawer - pain is a powerful guide to decision making,
I would more than gladly be PAR's first revenue - how about a discount Paul?
Numbers can certainly be consolidated through this SAS for...
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |